Digital inhalers may help predict occurrence of acute exacerbations of COPD for patients in an ambulatory setting.

Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being ...